The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

2002 • 4,076 citations

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2001 • 3,631 citations

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

1997 • 3,152 citations

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

1976 • 3,140 citations

Development of a Crohn's Disease Activity Index

1976 • 3,024 citations

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

2000 • 2,992 citations

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

1999 • 2,656 citations

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

1999 • 2,358 citations

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

1999 • 2,117 citations

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

2003 • 1,990 citations

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

2003 • 1,933 citations

The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death

1994 • 1,920 citations

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

2004 • 1,787 citations

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 • 1,750 citations

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1998 • 1,642 citations

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

2003 • 1,504 citations

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

2000 • 1,463 citations

Etanercept Therapy in Rheumatoid Arthritis

1999 • 1,407 citations

The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

1982 • 1,303 citations

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

2002 • 1,272 citations

INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS

2000 • 1,181 citations

Etanercept as Monotherapy in Patients with Psoriasis

2003 • 1,167 citations

Targeted Anticytokine Therapy in Patients With Chronic Heart Failure

2004 • 1,148 citations

Guidelines for the management of rheumatoid arthritis: 2002 Update

2002 • 1,062 citations

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report

2003 • 1,009 citations

TNF neutralization in MS

1999 • 968 citations

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

2001 • 913 citations

Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

2001 • 910 citations

Guidelines for the Management of Rheumatoid Arthritis 2002 Update

2002 • 863 citations

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

1989 • 833 citations

Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides

2001 • 813 citations

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1999 • 755 citations

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

2003 • 747 citations

Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α

2002 • 679 citations

Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients

2004 • 643 citations

Incidence of Cancer Among Patients With Rheumatoid Arthritis

1993 • 596 citations

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial

2003 • 561 citations

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

2000 • 535 citations

Psoriasis

2003 • 533 citations

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

2003 • 498 citations

The Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience

2003 • 489 citations

TREATMENT OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a

2002 • 482 citations

Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

2003 • 450 citations

Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept

2002 • 444 citations

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

2003 • 431 citations

Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study

2001 • 427 citations

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

1998 • 394 citations

Rheumatoid arthritis and cancer risk

1996 • 385 citations

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti–tumor necrosis factor therapy

2004 • 370 citations

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

2003 • 357 citations

[Etanercept for therapy of rheumatoid arthritis].

2005 • 344 citations

Guidelines for the Management of Rheumatoid Arthritis

2002 • 321 citations

Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

2004 • 288 citations

Epstein-Barr virus–positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine

2002 • 271 citations

Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first‐degree relatives

2003 • 270 citations

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make sense

2003 • 229 citations

The risk of malignancy associated with psoriasis.

2001 • 224 citations

Increased risk of tuberculosis in patients with rheumatoid arthritis.

2003 • 224 citations

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

2003 • 222 citations

Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety

2001 • 220 citations

Behcet's disease: a new target for anti-tumour necrosis factor treatment

2002 • 197 citations

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

2000 • 197 citations

Anti-TNF-?-induced systemic lupus syndrome

2003 • 187 citations

Cyclosporine consensus conference: With emphasis on the treatment of psoriasis

1998 • 184 citations

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

2003 • 176 citations

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis

2002 • 175 citations

Hidradenitis Suppurativa and Crohn's Disease: Response to Treatment with Infliximab

2001 • 163 citations

The Effects of Infliximab Maintenance Therapy on Health-Related Quality of Life

2003 • 126 citations

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.

2004 • 120 citations

Co-morbidity in rheumatoid arthritis

2003 • 116 citations

Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab

2002 • 112 citations

Etanercept ameliorates sarcoidosis arthritis and skin disease.

2003 • 111 citations

Infliximab for patients with refractory ulcerative colitis

2001 • 108 citations

Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis

2003 • 105 citations

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept

2002 • 101 citations

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study

2003 • 99 citations

Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents

2002 • 95 citations

Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-? therapy

2003 • 91 citations

Infliximab (Anti–Tumor Necrosis Factor α Antibody)

2001 • 90 citations

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis

2002 • 86 citations

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

2002 • 85 citations

Infliximab therapy for sarcoidosis (lupus pernio)

2004 • 77 citations

Etanercept-induced systemic lupus erythematosus

2003 • 76 citations

Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

2003 • 76 citations

Infliximab as a Novel Therapy for Pediatric Ulcerative Colitis

2002 • 72 citations

Infectious complications of biologic treatments of rheumatoid arthritis

2003 • 70 citations

Tuberculosis in the cytokine era: What rheumatologists need to know

2003 • 69 citations

Inflammatory Bowel Disease and Pregnancy

2001 • 67 citations

Infliximab-induced lupus in Crohn’s disease: a case report

2003 • 64 citations

Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis.

2003 • 61 citations

The use of infliximab in cutaneous sarcoidosis.

2003 • 55 citations

Methotrexate in psoriasis

1980 • 51 citations

The Incidence of Lymphoid and Myeloid Malignancies Among Hospitalized Crohn’s Disease Patients

2001 • 47 citations

Maintenance infliximab for Crohn's disease

2002 • 43 citations

Comorbid conditions in patients with rheumatic diseases: an update

2004 • 36 citations

Outcome of pregnancy in women receiving REMICADE® (Infliximab) for the treatment of Crohn's disease or rheumatoid arthritis

2001 • 35 citations

Pharmacovigilance: towards a better understanding of the benefit to risk ratio

2002 • 30 citations

Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis.

2001 • 27 citations

Etanercept in the treatment of psoriatic arthritis and psoriasis

2000 • 27 citations

Hidradenitis Suppurativa and Crohn’s Disease

2006 • 10 citations

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis

2001 • 5 citations

Infliximab is not a bridge to immunomodulators in Crohns disease

2003 • 3 citations

Infliximab in the Treatment of Psoriasis

2003 • 3 citations

Response to infliximab in fistulizing Crohn?s disease is independent of baseline number of draining fistulas

2003 • 1 citations

RESPONSE TO INFLIXIMAB IN FISTULIZING CROHNʼS DISEASE IS INDEPENDENT OF BASELINE NUMBER OF DRAINING FISTULAS

2003 • 1 citations